ClinicalTrials.gg
CompletedNCT05924152Updated Mar 13, 2024

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

A Phase 1 interventional study of Adagrasib and Eltrombopag + adagrasib in Healthy Adults, sponsored by Mirati Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Mirati Therapeutics Inc. is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 4 (20%) have results posted.

First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, of any race, between 18 and 60 years of age, inclusive, at Screening.
  2. between 18.0 and 32.0 kg/m2, inclusive, at Screening.
  3. In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, or clinical laboratory evaluations at Screening and Check-in as assessed by the Investigator.
  4. Females of will not be pregnant or lactating and must have a negative result on an approved pregnancy test at Screening and Check-in. Females of childbearing potential must agree to use .
  5. Male subjects must agree to use contraception.
  6. Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, thrombotic, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator.
  2. History of significant , intolerance, or allergy to any drug compound, food, any components of the product (IP), or other substance (not including seasonal allergies).
  3. History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome).
  4. Significant history or clinical manifestation of any hepatic disease, as determined by laboratory abnormalities.
  5. History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study.
  6. Ventricular dysfunction or history of risk factors for Torsades de Pointes.
  7. History of drug abuse within 2 years prior to Screening.
  8. History of alcohol abuse within 12 months prior to Screening.
  9. Positive serology test results for surface antigen, antibody, and/or (HIV) 1/2.
  10. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
  11. Use of any drugs or substances known or suspected to alter drug absorption, distribution, metabolism, or elimination.
  12. Use or intend to use any prescription medications/products within 14 days prior to Check-in.
  13. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations.
  14. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days.
  15. Subjects who, in the opinion of the Investigator, should not participate in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Treatment A

    Treatment A: A single oral dose of adagrasib 400 mg (2 × 200-mg tablets) on Day 1;

    Drug: Adagrasib

  • Active comparator
    Treatment B

    Treatment B: A single oral dose of eltrombopag 75 mg (1 × 75-mg tablet) plus adagrasib 400 mg (2 × 200-mg tablets) on Day 8.

    Drug: Eltrombopag + adagrasib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - AUC (adagrasib)

    Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC∞)

    Time frame: Days 1 and 8

  2. Pharmacokinetics - AUC (adagrasib)

    AUC from time zero to the last quantifiable concentration (AUClast)

    Time frame: Days 1 and 8

  3. Pharmacokinetics - Cmax (adagrasib)

    Maximum observed plasma concentration (Cmax)

    Time frame: Days 1 and 8

  4. Pharmacokinetics - Tmax (adagrasib)

    Time to reach Cmax (tmax)

    Time frame: Days 1 and 8

  5. Pharmacokinetics - t1/2 (adagrasib)

    Elimination half-life (t1/2)

    Time frame: Days 1 and 8

  6. Pharmacokinetics - CL/F (adagrasib)

    Apparent total plasma clearance (CL/F)

    Time frame: Days 1 and 8

  7. Pharmacokinetics - Vz/F (adagrasib)

    Apparent volume of distribution (Vz/F)

    Time frame: Days 1 and 8

Secondary outcomes

  1. Adverse Events (AEs)

    Incidence and severity of AEs

    Time frame: Up to 8 weeks from screening

07

Study locations

1 site
  • Fortrea Clinical Research Unit Daytona Beach (Labcorp Clinical Research Unit Daytona Beach)
    Daytona Beach, Florida 32117, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Aug 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2023
First posted
Jun 29, 2023
StartActual
Jun 29, 2023
Primary completionActual
Aug 9, 2023
CompletionActual
Aug 17, 2023
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05924152
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Jun 29, 2023
Primary completion
Aug 9, 2023
Completion
Aug 17, 2023
Last update
Mar 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adagrasib · Eltrombopag

Start the discussion